Please ensure Javascript is enabled for purposes of website accessibility
Max Macaluso

Max Macaluso

TMFMassimo

Max is the Technology, Biopharma & Health Care Bureau Chief at Fool.com. Prior to joining the Fool, he completed a PhD in chemistry at the University of Cambridge and an MBA at the College des Ingenieurs.

Recent articles

An Interview With Portola Pharmaceuticals CEO Bill Lis

Motley Fool analyst Max Macaluso discusses Portola Pharmaceuticals' pipeline and approach to research and development with CEO Bill Lis.


Better Buy: CONSOL Energy vs. Gilead Sciences

We've collected the most popular companies among Fool.com readers and put them head-to-head in a good old-fashioned challenge we're calling The Motley Fool Better-Buy Tournament.


Better Buy: Gilead Sciences vs. Berkshire Hathaway

We've collected the most popular companies amongst Fool.com readers and put them head-to-head in a good old-fashioned challenge we're calling The Motley Fool's Better Buy Tournament.


Better Buy: Enterprise Products Partners vs. Amgen

We've collected the most popular companies amongst Fool.com readers and put them head-to-head in a good old-fashioned challenge we're calling The Motley Fool Better-Buy Tournament.


Ranking Big Pharma's Top Drugs of 2013

Ranking the pharma industry's three biggest winners of 2013.

Better Buy: Netflix vs. Gilead Sciences

We've collected the most popular companies amongst Fool.com readers and put them head-to-head in a good old-fashioned challenge we're calling The Motley Fool Better-Buy Tournament.


3 Prescription Drugs You Didn't Know Come From Marijuana

A close look at three prescription drugs you probably didn't know come from one of the world's most controversial plants: cannabis.


The Spark of Innovation at Vertex Pharmaceuticals Incorporated

Motley Fool analyst Max Macaluso discusses how Vertex Pharmaceutical's culture helped the company develop break-through medications with author Barry Werth.


4 Keys to Vertex Pharmaceuticals' Success

Motley Fool analyst Max Macaluso discusses the keys to Vertex Pharmaceuticals' success with Barry Werth, author of "The Antidote: Inside the World of New Pharma."


Ask a Fool: What Is Your Foolish Opinion of Horizon Pharma?

Here's one analyst's Foolish take on this explosive biotech stock.

From Startup to Billion-Dollar Biotech: An Inside Look at Vertex Pharmaceuticals

An interview with Barry Werth, author of "The Antidote: Inside the World of New Pharma."


Why Novartis Is One of Today's Most Innovative Companies

What makes Novartis stand out from the crowd?


Marijuana Stocks: A Real Investing Opportunity or Not Worth the Hype?

There has been a lot of hype around marijuana stocks lately, but is this market too immature to invest in today?


Dividend Stock To Watch Today: Sanofi

This is why investors should get Sanofi on their watchlist.


Big Pharma Diversification: A Winning Model or Recipe for Disaster?

Should big pharma companies stick to diversified business models, or should they double down on drug development?

Medicine and Gaming: The Surprising Link You (Probably) Don't Know About

The worlds of medicine and gaming aren't as far apart as you might think.


AstraZeneca Stock: 1 Red Light, 1 Green Light

One pro and one con for investors looking at AstraZeneca today.


Can Teva Rebound After This Rejection?

Teva got some very bad news last week. Will the company be able to bounce back?


Sanofi Stock: Will This Be a Big Pharma Winner in 2014?

Could Sanofi's strategy help boost returns this year, despite its lackluster 2013?


Eli Lilly Stock: 1 Red Light, 1 Green Light

Eli Lilly had a rough 2013, but the yield is attractive. Is this a good point to jump in?